Esteve Pharmaceuticals, S.A.

After a lengthy back-and-forth with Avenue Therapeutics, Inc. , the US Food and Drug Administration is asking its advisory committees to vote on whether the benefits of the intravenous formulation of

Scrip regularly covers business development and deal-making in the biopharmaceutical industry. Deal Watch is supported by deal intelligence from Biomedtracker. AstraZeneca To Study ‘Elite Controller’

Barcelona, Spain-based AELIX Therapeutics ’s proprietary T-cell immunogen has shown a signal of therapeutic benefit in an early clinical study, and the biotech is now aiming to raise series B financi

Japan’s Towa Pharmaceutical has completed its €329m ($364m) deal to acquire the [Pensa Investments] generics business from Spain’s Esteve . The closure of the deal, through which Pensa has now beco